Agmatine depletes cellular polyamines and slows hepatoma cell growth in a dish. It is also lower in the blood of prostate cancer patients. Neither finding says what supplement marketing wants it to say.
In Alzheimer’s models, brain agmatine falls and its degrading enzyme rises. That biomarker story is better supported than any claim that supplementing agmatine treats Alzheimer’s.
A rat study put agmatine head-to-head against methylprednisolone after spinal cord injury. Both cut oxidative damage markers – here’s what that does and doesn’t mean.
The first published measurement of agmatine’s oral bioavailability (29-35%), its real half-life in brain versus plasma, and why spinal cord distribution lags behind brain.
No agmatine-specific perioperative trial exists, but general supplement-discontinuation guidance applies directly given its blood pressure and blood sugar effects. A practical pre-op safety guide.
A 2020 open-label pilot study gave agmatine sulfate to small fiber neuropathy patients for two months and measured a 46% drop in pain. Here’s exactly what the trial did, who it studied, and why it isn’t proof yet.
Agmatine reduces tactile allodynia and lowers glucose in streptozotocin-diabetic rat studies. Here’s what the animal evidence actually shows, and why no diabetes-specific human trial exists yet.